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erman embryonic stem cell scientist Oliver Brustle 
faces major challenges in his lab on a daily basis that 
have little to do with science. His country’s policy 
on human embryonic stem cells (hESCs) is among the most 
restrictive in Europe. Collaborations with other countries are 
difficult. And he’s overwhelmed by the time and paperwork 
necessary to comply with regulations and to apply for permits. 
Brustle, an investigator at the University of Bonn (Bonn, 
Germany), often ponders the possibility of taking his work 
elsewhere. “I think about it every day,” 
he says. “Sometimes [the regulations] 
get to the point where they’re 
suffocating.” Many of his German 
colleagues have similar sentiments, he 
says. In Germany, scientists can only 
work on hESC lines derived in labs 
outside the country, and even then, only 
if the line was derived prior to 2002. 
Federal law prohibits the derivation of 
new hESC lines.
Yet Brustle is optimistic that hESC 
technology, flush with research dollars 
in many countries and garnering interest 
worldwide, is destined for greatness. He 
takes solace in the fact that his long-time 
scientific pursuit has potential for success 
on several different fronts. Indeed, 
though some hESC scientists like Brustle 
are frustrated, others are thriving.
The most recent front is California, 
where Proposition 71 [1], passed last 
November, sent science policy shock 
waves across the United States and 
around the world (Box 1). Promising 
an impressive US$3 billion in funding 
for hESC research over the next ten 
years, “Prop 71” could further complicate an already complex 
landscape of laws and funding sources (assuming supporters 
can prevail over legislation that has stalled the measure). 
Other states in the US are struggling to catch up, setting the 
stage for a patchwork of policies and funding efforts. 
Countries from Europe to Asia also have a patchwork 
of different policies (Figure 1), as economic and scientific 
interests clash with religious and cultural mores in a battle 
over research that has yet to help a single patient. And while 
many non-Californian stem cell researchers are cheering the 
Prop 71 windfall, they’re wary of brain drain to California in 
a field that already has a shortage of talent. Some supporters 
also worry that a mosaic of state laws will make collaborations 
more difficult and future therapies hard to administer. In 
short, Prop 71 is likely to help shape the future of stem cell 
research in the US and around the world.
An Intriguing Proposition
Stanford University (Stanford, California, United States 
of America) stem cell scientist Irv Weissman, who played 
a key role in the multimillion dollar effort that recruited 
researchers, advocates, and Hollywood actors to support Prop 
71, attributes the effort’s inception to a 2002 US National 
Academy of Sciences report on cloning. It contended that 
therapeutic cloning, or somatic cell nuclear transfer (SCNT), 
could be used to generate disease-specific stem cell lines; 
the research had more future applications than just cell and 
organ transplantation (Box 2). Scientists might be able to 
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Figure 1. Stem Cell Policy Map
Countries colored in brown have a permissive or ﬂ  exible policy on human embryonic stem 
cell research. All have banned human reproductive cloning. These countries represent 
about 3.4 billion people, more than half the world’s population. “Permissive” (countries in 
dark brown) means that various embryonic stem cell derivation techniques are permitted, 
including SCNT. “Flexible” (countries in light brown) means that stem cells may be derived 
from human embryos donated by fertility clinics only, excluding SCNT. Countries in yellow 
have either a restrictive policy or no established policy.
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actually revert diseased cells to their primordial form and then 
monitor them to see how and why abnormalities develop. 
That notion sparked interest from many people unhappy 
with President Bush’s policy, which dictates that no federal 
funding may be used to work on hESC lines derived after 
August 2001. (On May 24 the US House of Representatives 
passed a bill that would make more cell lines available for 
federal funding. Bush has vowed to veto the bill.) Also of 
concern: stem cell lines approved by the National Institutes of 
Health (NIH) (http:⁄⁄stemcells.nih.gov/research/registry/), 
which can only be grown on a layer of mouse feeder cells, 
would not be appropriate for clinical use since animal viruses 
could theoretically jump to humans. According to some, the 
president’s policy was simply too restrictive.
And then Hollywood got involved. Producers Janet 
and Jerry Zucker, who have a child with diabetes, asked 
Weissman to educate them about stem cells, which led to 
the formation of an advocacy organization called CuresNow 
(Los Angeles, California, United States of America). State 
Senator Debra Ortiz took up the cause, and suggested that 
California support research where the NIH could not. Soon 
after, the politically savvy Robert Klein, a board member 
of the Juvenile Diabetes Foundation, began spearheading 
the Prop 71 effort. (Klein has a child with diabetes as well.) 
Weissman and other scientists conducted dozens of talks, 
educating the public about stem cells and cautioning them 
about the potentially slow pace of hESC research. Governor 
Arnold Schwarzenegger decided to endorse the plan. And in 
November of last year, voters voiced their approval. 
Though some states already had initiatives under way, 
Prop 71 spurred and accelerated efforts. Many states are now 
engaged in a race to attract stem cell research with laws and 
regulations that defy the Bush administration policy. In some 
cases, states are pushing for funding packages to offset the 
federal funding shortfall and insure that their most promising 
scientists don’t head west. And in other cases, states are 
reacting strongly in the opposite fashion, considering major 
restrictions on the sort of stem cell research that scientists in 
their state can conduct. 
“As this issue has hit the state level, there has been a 
noticeable change in the terms of the debate” says Daniel 
Perry, executive director of Coalition for the Advancement of 
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Figure 2. Embryonic Stem Cells 
(A) shows  hESCs.
(B) shows neurons derived from hESCs.
(Images: Nissim Benvenisty)
Economic and scientiﬁ  c interests clash 
with religious and cultural mores in 
a battle over research that has yet to 
help a single patient.
Box 1. Proposition 71
California’s Proposition 71 calls for US$3 billion of stem cell 
research funding over 10 years. The money will be raised by 
general fund bonds. The measure includes the establishment 
of the California Institute for Regenerative Medicine (http://
www.cirm.ca.gov/) to regulate and oversee stem cell research, 
a mission that entails managing ethical research practices 
and awarding grants through peer review (peer reviewers will 
be based outside the state of California). The Institute’s 29-
member Independent Citizens Oversight Committee consists of 
representatives from California universities, nonproﬁ  t institutions, 
patient advocacy groups, and the biotechnology industry. Grant 
reviews will be by out-of-state scientists to prevent conﬂ  icts of 
interest. Unlike the policy dictated by President Bush in August 
2001, Prop 71 permits the funding of the derivation of new 
human embryonic stem cell lines, including via SCNT research 
(therapeutic cloning). Currently, 78 hESC lines around the 
world are eligible for federal US funding, but only 22 have been 
developed into distribution-quality cell lines. With interest, Prop 
71 is projected to cost the state approximately US$6 billion if 
paid over a 30-year period. Lawsuits attempting to stop Prop 
71 are currently pending, according to a spokesperson for the 
California Institute for Regenerative Medicine. It’s not yet clear, 
she said, for how long the litigation will stall the sale of bonds 
and the awarding of research dollars. 
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Medical Research (Washington, District of Columbia, United 
States of America), which represents patient organizations, 
universities, scientific societies, and foundations. Before 
Proposition 71, moral status questions were at the fore, e.g., 
debates as to when life begins and how society should balance 
the rights of a potential life with those of a person suffering 
from a life-threatening disease. “Now the debate is all about 
economic development,” says Perry. “Are we going to be 
creating jobs in Delaware or Illinois or Pennsylvania or are 
we going to be losing them to states next door that are in the 
stem cell business?” Stem cell research supporters fear their 
states, many with a history of biotechnology and life sciences 
investment, will lose talent, dollars, and infrastructure to 
California or other states if they don’t protect their own 
research investment.
State by State
More than 30 US states are considering some sort of 
legislation related to stem cell research, for or against. 
Particularly active, according to Perry, are Wisconsin, 
Illinois, New York, Delaware, Texas, Florida, Washington, 
and Missouri. In Illinois, the state house and senate are 
considering a bill that imposes a surcharge on elective 
cosmetic surgery as a way to raise an estimated US$1 billion 
for stem cell research over the next ten years. In New Jersey, 
with the support of Governor Richard Cody, the legislature 
approved US$150 million in state funding to build a Stem 
Cell Institute. New Jersey citizens will vote on a US$230 
million bond this November that would finance stem cell 
research over the next seven years. Connecticut recently 
approved $100 million for stem cell research.
The senate and house in Massachusetts recently voted to 
explicitly allow all aspects of stem cell research, including 
work on surplus embryos and SCNT. Legislators had enough 
votes to override Massachusetts governor Mitt Romney’s 
veto. “For those of us worried that everything could get 
shut down, this is a big relief,” says Leonard Zon, a Howard 
Hughes Medical Institute (Chevy Chase, Maryland, United 
States of America) investigator and the director of the stem 
cell research program at Children’s Hospital Boston (Boston, 
Massachusetts, United States of America). Zon, who works 
on deriving blood stem cells from embryonic stem cells, 
spent considerable time helping to support the legislation. 
Massachusetts has some high-profile stem cell researchers, 
and many feared that California would be too tantalizing to 
resist. According to a spokesperson for Romney, the governor 
supports hESC research but not SCNT. He contends that only 
a few Massachusetts companies are actually focused on stem 
cell research, and hence he’s not concerned about scientists 
migrating west en masse.
In Maryland, a bill to fund hESC research was narrowly 
defeated in April of this year after months of political 
wrangling by a divided legislature. Like Governor Romney, 
Republican governor Robert Ehrlich supports, according to 
a spokesperson, embryonic stem cell research and President 
Bush’s policy. But he has taken no official position on SCNT, 
nor on the recently defeated bill (which never actually got 
to his desk). Using money garnered from cigarette company 
restitution, the bill would have funneled US$25 million 
to embryonic stem cell research on discarded embryos, 
but would not have supported SCNT. Many in Maryland 
are keen to protect the state’s life sciences investment. 
Already, though, California schools are making inquiries. 
“We certainly are having our share of people who are being 
recruited away at all levels,” says John Gearhart, a professor 
of biochemistry and molecular biology at Johns Hopkins 
University (Baltimore, Maryland, United States of America) 
and one of the first scientists to derive pluripotent human 
stem cells in 1998 (Figure 2). Gearhart is encouraged 
that the bill came within one vote of passing, and hopes 
that supporters will have better luck in the next legislative 
session. But he notes that time is running out; the Maryland 
legislature doesn’t meet again until January of 2006, and any 
program that’s approved would require a couple of years to 
ramp up.
Other states, actually acting prior to Prop 71 based on 
concerns about researchers doing any sort of cloning, 
therapeutic or otherwise, have enacted outright restrictions, 
DOI: 10.1371/journal.pbio.0030234.g003
Figure 3. Ariff Bongso
Ariff Bongso is a professor of obstetrics and gynecology and a 
pioneer of human embryonic stem cell research at the National 
University of Singapore.
Johns Hopkins president William 
Brody calls the growing inﬂ  uence 
of state legislators on the lab 
“scientiﬁ  c tourism.”
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mostly with regard to SCNT. Arkansas, North and South 
Dakota, Iowa, and Michigan all have laws specifically 
restricting aspects of hESC research. A Missouri state senate 
bill that would have criminalized SCNT recently stalled. 
In some states, including Texas, Illinois, and New York, 
lawmakers have proposed bills both for and against stem cell 
research.
Best of a Bad Regulatory Situation
Despite the positive activity in many places, researchers like 
Gearhart and Weissman admit that it’s only the best of a bad 
situation. A blanket federal funding policy would be much 
preferable. “I like to say that the glass is half full,” says Carl 
Gulbrandsen, director of the nonprofit WiCell Research 
Institute, which supports human embryonic stem cell 
research at the University of Wisconsin-Madison (Madison, 
Wisconsin, United States of America). Gulbrandsen 
distributes hESC lines derived by Wisconsin stem cell 
researcher Jamie Thomson, another pioneer of hESC 
research. It’s encouraging, notes Gulbrandsen, that a large 
state like California, already suffering from severe deficit, 
has supported stem cell research. And Prop 71 has raised the 
value of the research in terms of licensing opportunities, with 
companies, both biotechs and pharmas, showing increased 
interest. 
But Prop 71 also promises to increase the cost of doing 
research by making the attraction and retention of faculty 
more expensive as California and potentially other states offer 
millions in grants and salaries to stem cell researchers. “It’s 
going to be very difficult,” says Gulbrandsen. “We’re going 
to have to open the pocketbook and spend a lot of money 
to make sure the research goes forward.” In general, the 
state-by-state funding model “is a very poor public policy,” he 
adds. “If you end up with a patchwork of regulations, you’re 
going to both decrease the movability of scientists and you’re 
going to discourage collaborations.” Gulbrandsen suggests 
that intellectual property could be an issue as well, with 
states passing their own regulations, controlling their own 
intellectual property, and hence potentially creating turf wars 
among themselves and conflicts with federal policy. He says, 
“It’s not a good road to walk down.” 
Johns Hopkins president William Brody, though he 
supported funding efforts in Maryland, calls the growing 
influence of state legislators on the lab “scientific tourism.” 
“It’s just going to create havoc about what you can do where, 
and I don’t think in the end it’s good science policy or good 
health care policy,” he says, noting that many states have 
actually restricted the research, in effect putting in place 
harsher regulations than those of the federal government. 
And regulations in other types of research could follow, 
Brody contends.
The quality of the research is at issue as well. Brody 
worries that smaller states won’t be able to replicate rigorous 
grant peer review. Weissman is most concerned that the 
considerable monies available could lead to the wasting 
of funding on sub-par research. He advocates carrying 
the money forward until it can be well spent, perhaps on 
expensive clinical trials that are years away.
The Proposition Heard around the World
Meanwhile, researchers overseas are taking notice of Prop 
71, also with a mix of support and trepidation. “There’s been 
a little bit of complacency in Europe because of the Bush 
decree,” says Austin Smith, director of the Institute for Stem 
Cell Research at the University of Edinburgh (Edinburgh, 
United Kingdom), and coordinator of EuroStemCell 
(Edinburgh, United Kingdom), an international consortium 
for stem cell research funded by the European Union. 
“European institutions have got to get their act together, 
because otherwise all our best people will go to California or 
other states setting up programs.” Alan Trounson, director 
of Monash Institute of Reproduction and Development in 
Clayton, Australia, has little doubt that California’s stem cell 
funding riches will drain away talent from down under. “It 
will certainly be a very attractive place for young people and 
mid-career people to go,” he says, noting that Prop 71 should 
help give young stem cell investigators confidence that their 
field has a secure future.
Laws regulating hESC research in Europe and around the 
world vary considerably. Countries like the United Kingdom, 
Germany’s European Commission 
stem cell research contribution ends 
up being funneled to countries with 
more liberal policies.
Box 2. Sources of hESCs
Researchers primarily obtain human embryonic stem cells 
from frozen embryos donated by IVF programs. Cell lines may be 
grown by isolating hESCs from the inner cell mass of a human 
blastocyst, a ﬁ  ve-day-old embryo. These cells are cultured 
indeﬁ  nitely with the help of ﬁ  broblast feeder layers. Several 
groups are now attempting to grow feeder-free cell lines, which 
would enable investigators to know exactly what molecular 
factors are contributing to hESC growth [2]. According to Austin 
Smith, director of the Institute for Stem Cell Research at the 
University of Edinburgh, if scientists can discover the minimum 
requirements for self-renewal, they’ll be able to better control 
and direct robust hESC growth, which could be advantageous for 
both basic and clinical hESC research.
Researchers may also obtain hESCs via SCNT, as was 
demonstrated last year by a group in South Korea [3]. The 
technique involves removing the nucleus, and hence the nuclear 
genome, of an oocyte and replacing it with the nucleus of an 
adult cell. The activated egg can then form a blastocyst, which 
contains identical genetic material to that of the donor adult cell, 
and this is the process often referred to as therapeutic cloning. 
By using SCNT rather than a donated IVF embryo, researchers 
would be able to control the genotype of hESCs, which could 
help circumvent tissue rejection problems in future clinical 
applications as well as help investigators study the development 
of diseases via disease cell lines. In May, Hwang et al. became the 
ﬁ  rst to derive patient-speciﬁ  c human embryonic stem cells from 
SCNT blastocysts [4]. Even when countries allow SCNT, lawfully 
securing donated oocytes can be a challenge. Last year, Hwang 
et al. [3] used 200 oocytes before deriving a single cell line. His 
more recent study [4] was much more efﬁ  cient. His group’s 
work has yet to be widely repeated. If implanted in a uterus, a 
blastocyst generated via nuclear transfer could theoretically 
develop into a human being genetically identical with the 
nuclear donor.
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Sweden, and Singapore are among the most liberal. In the 
UK, researchers are allowed to use embryonic stem cells from 
discarded embryos, and they’re allowed to create embryos 
for the purposes of research. The approval process, however, 
can be laborious, according to Smith, though it has improved 
considerably in the last couple of years. Researchers must 
get approval from their local hospital ethical board, then 
they must apply for a license from the Human Fertilisation 
and Embryology Authority. HFEA inspects the quality of 
the science, the researcher’s justification for using human 
embryos, whether scientists are complying with the law, and 
whether they’re following correct patient consent procedures. 
Once a license is granted, HFEA conducts yearly inspections 
to insure that every embryo is accounted for. 
In the beginning of April 2005, Sweden’s government 
specifically approved of producing embryonic stem cell 
lines using SCNT. Using hESCs from leftover embryos had 
already been allowed. Protections in place are akin to those 
of the UK. “I’m very happy with the Swedish law,” says Outi 
Hovatta, a stem cell researcher at the Karolinska Institutet in 
Stockholm, Sweden. “There are clear regulations. We know 
what we can do, and we know what we can’t do.” 
After a year of public education outreach that included 
discussions with bioethicists, scientists, and religious leaders, 
Singapore, having already invested substantial federal funds 
into the life sciences, established specific hESC regulations. 
The rules allow research on surplus in vitro fertilization 
(IVF) embryos using federal funding, and allow SCNT on a 
case by case basis. They also prohibit reproductive cloning; 
anyone caught attempting reproductive cloning receives 
a S$100,000 fine and ten years in jail. “I’ve never seen so 
much support from a government when it comes to stem 
cell biology,” Ariff Bongso, a professor of obstetrics and 
gynecology at the National University of Singapore (Figure 
3). Bongso was the first person to isolate embryonic stem cells 
from human embryos in 1994. To derive hESCs, researchers 
must go to the hospital institutional review board, then to the 
government ministry of health, then to a government advisory 
bioethical council. Stem cell excitement has reached a fever 
pitch in Singapore, according to Bongso. “Everybody’s talking 
about stem cells,” he says.
Countries like Israel and Australia have somewhat liberal 
laws, thought not quite as permissive. In Australia, laws used 
to be state by state, and cell lines could only be harvested 
from IVF embryos frozen prior to 2002. But a federal law 
now permits research on any frozen embryo, with the usual 
consent and ethical review. For now, SCNT has not been 
endorsed. In Israel, researchers can use embryonic stem 
cells from frozen embryos, but egg donation is not allowed, 
making SCNT all but impossible. Nissim Benvenisty, a 
stem cell researcher at the Hebrew University of Jerusalem 
(Jerusalem, Israel), says that many families are happy to 
donate discarded embryos that have been diagnosed with 
genetic diseases so that researchers can study diseased cell 
development. Countries like Switzerland, Spain, and France 
allow stem cell research with some restrictions. 
Austria and Germany are much more restrictive. Brustle 
attributes his country’s regulations to religious views, a legacy 
of eugenics, and negative attitudes towards new technologies. 
Brustle finds it difficult to conduct collaborations and he 
finds funding set-up somewhat nonsensical. For example: 
The European Commission, which will fund established stem 
cell lines, has a more liberal policy than Germany. Germany’s 
European Commission stem cell research contribution ends 
up being funneled to countries with more liberal policies. 
Germany, then, indirectly pays for research in other countries 
that it actually deems illegal.
European collaborative efforts, though, continue to 
pick up steam. EuroStemCell, organized via the European 
Union, has 27 different member labs throughout Europe, 
with interests in adult and embryonic stem cells, clinical 
and basic research. According to Smith, the organization’s 
charge is the exchange of materials and people. Smith would 
like to build up a cadre of European researchers trained 
in stem cell biology. “We have to collaborate in Europe to 
be competitive with the US,” he says. “It’s not so clear that 
that’s an imperative if you’re sitting in California with all that 
money.”  
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